Novo Nordisk Navigates Q2 2026 Setbacks: Wegovy Pill Sales Miss and CagriSema Clinical Failure

Novo Nordisk Navigates Q2 2026 Setbacks: Wegovy Pill Sales Miss and CagriSema Clinical Failure

Novo Nordisk's commercial and clinical momentum faced significant hurdles in Q2 2026, driven by a sales miss for its highly anticipated oral Wegovy pill and a major clinical trial disappointment for its next-generation obesity candidate, CagriSema. Despite these setbacks, the company remains highly competitive in the oral obesity segment, capturing the vast majority of the market share.

Commercial Performance and Wegovy Pill Miss

Novo Nordisk reported Q2 2026 adjusted sales growth of 7% YoY (at Constant Exchange Rates, or CER) to DKK 78.5 billion, with adjusted operating profit increasing by 11% CER to DKK 33.4 billion (~$5.15 billion). However, the highly watched Wegovy pill (oral semaglutide) underperformed Wall Street expectations.

According to BioPharma Dive:

"In the second quarter, the Wegovy pill had sales of 3.2 billion Danish kroner, or about $494 million, less than the 3.6 billion kroner expected by analysts.¹ Novo’s shares fell 6% Tuesday before recovering some of their losses Wednesday."

Despite the revenue miss, the Wegovy pill's volume launch remains exceptionally strong. On the Q2 2026 earnings call, Novo Nordisk leadership highlighted its massive market share dominance:

"The Wegovy pill is the strongest-ever GLP-1 launch by volume, and we have now reached over 5 million total prescriptions. Yet the latest 1 million TRx were added in just four weeks. Based on the latest data, in the face of competition launched in early April, the Wegovy pill has captured around 90% of the oral obesity medication market. We also find people coming to Wegovy pill from competitor products and limited cannibalization on injectable Wegovy, which is encouraging."

Clinical Setback for CagriSema

Novo Nordisk suffered a major clinical blow with its next-generation weight-loss and diabetes candidate, CagriSema (a once-weekly fixed-dose combination of semaglutide and cagrilintide). In the head-to-head Phase 3 REIMAGINE 4 trial, CagriSema failed to demonstrate superior efficacy over Eli Lilly’s tirzepatide (Mounjaro) in blood sugar control.

According to BioPharma Dive:

"Novo’s report Tuesday disappointed investors on two fronts. Its experimental CagriSema medicine failed to control blood sugar as well as Lilly’s tirzepatide in a head-to-head trial of patients with Type 2 diabetes.²"

This setback is a significant commercial headwind, as Novo Nordisk had positioned CagriSema as its primary weapon to counter Eli Lilly's market-share gains in both the diabetes and obesity segments.

Structural Restructuring and Outlook

To optimize its cost structure amid lower realized prices and intensifying competition, Novo Nordisk has executed a massive headcount reduction over the past year. During the Q2 2026 earnings call, management noted:

"At the end of the second quarter, the number of full-time employees was around 66,700, which is a decrease of almost 12,000 employees corresponding to roughly a 15% decline compared to 12 months ago."

Novo adjusted its full-year guidance, narrowing its expected sales decline. The company now expects adjusted sales at constant exchange rates to range from flat to a decline of 6%, an improvement over its previous guidance of a 4% to 12% decline.